Routes of
administration Oral Biological half-life 6–7 hours PubChem CID 9828911 Molar mass 546.7036 g/mol | ATC code None CAS Number 249921-19-5 ChemSpider 8004650 | |
 | ||
Dr abernethy discusses anamorelin as a treatment option for patients with cancer anorexia cachexia
Anamorelin (INN) (developmental code names ONO-7643, RC-1291, ST-1291), also known as anamorelin hydrochloride (USAN, JAN), is a non-peptide, orally-active, centrally-penetrant, selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) with appetite-enhancing and anabolic effects which is under development by Helsinn Therapeutics for the treatment of cancer cachexia and anorexia.
Contents
- Dr abernethy discusses anamorelin as a treatment option for patients with cancer anorexia cachexia
- Dr temel discusses her work on anamorelin for treating nsclc patients with anorexia and cachexia
- References
Anamorelin significantly increases plasma levels of growth hormone (GH), insulin-like growth factor 1 (IGF-1), and insulin-like growth factor-binding protein 3 (IGFBP-3) in humans, without affecting plasma levels of prolactin, cortisol, insulin, glucose, adrenocorticotropic hormone (ACTH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), or thyroid-stimulating hormone (TSH). In addition, anamorelin significantly increases appetite, overall body weight, lean body mass, and muscle strength, with increases in body weight correlating directly with increases in plasma IGF-1 levels.
As of February 2016, anamorelin has completed phase III clinical trials for the treatment of cancer cachexia and anorexia associated with non-small-cell lung carcinoma. Results of the studies were positive, and the drug is now in preregistration with the European Medicines Agency.[1]